Reprocell buys into cell therapy discovery services sector with Biopta takeover

By Gareth Macdonald contact

- Last updated on GMT

Reprocell buys Biopta for preclinical services business
Reprocell buys Biopta for preclinical services business

Related tags: Stem cell

Reprocell has entered the CRO space through the acquisition of preclinical discovery services Biopta.

The Japanese stem cell specialist said the takeover - financial terms of which have not been disclosed – will be followed by an investment to expand the range of services offered by Biopta at its facilities in Glasgow, Scotland and Maryland, US.

Biopta's core focus is using human tissues to assess the toxicity of drug candidates, which it claims provides a more prediction than traditional animal models.

Pharmaceutical industry demand for such services is growing according to Reprocell, which said the high cost and time it takes to complete assessments in animal models has prompted sponsors to look for alternatives.

Prior to the acquisition ReproCell’s focus was the development and production of reagents, cells and reprogramming kits for companies developing induced pluripotent stem cell (iPS) based therapeutics.

The Japanese firm said: “With our acquisition of Biopta and the addition of new drug discovery support services to our business line-up, we are able to offer both our main business of the supply of products to pharmaceutical manufacturers, as well as research outsourcing services​.”

Reprocell did not outline any target markets, however, policies introduced in November 2013 by the Japanese Government to boost cell and regenerative therapy development​ may provide the firm with a potential customer base.

UK connection

The Biopta deal also connects Reprocell to a UK network of specialist contractors with which Biopta partnered in February​ this year.

The network – which in addition to Biopta includes Molecular Profiles, XenoGesis, Aurelia BioScience, Reach Separations, Charnwood Molecular – was established to provide sponsors with contractors for each stage of the drug development process.

Related topics: Bio Developments, Bio-Outsourcing

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers